Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
NCT00086996 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Oxaliplatin and fluorouracil may make tumor cells more sensitive to radiation therapy and may kill more tumor cells. Giving chemotherapy and radiation therapy before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well giving oxaliplatin together with fluorouracil and radiation therapy works in treating patients who are undergoing surgery for stage II or stage III cancer of the esophagus or gastroesophageal junction.
Conditions Studied
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- PROCEDURE conventional surgery
- RADIATION radiation therapy
Study Locations (20)
California
- East Bay Radiation Oncology Center — Castro Valley
- Eden Medical Center — Castro Valley
- Valley Medical Oncology Consultants - Castro Valley — Castro Valley
- Valley Medical Oncology — Fremont
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles
- Highland General Hospital — Oakland
- Alta Bates Summit Medical Center - Summit Campus — Oakland
- Bay Area Breast Surgeons, Incorporated — Oakland
- CCOP - Bay Area Tumor Institute — Oakland
- Larry G Strieff MD Medical Corporation — Oakland
- Tom K Lee, Incorporated — Oakland
- Desert Regional Medical Center Comprehensive Cancer Center — Palm Springs
- Valley Care Medical Center — Pleasanton
- Valley Medical Oncology Consultants - Pleasanton — Pleasanton
- University of California Davis Cancer Center — Sacramento
- Doctors Medical Center - San Pablo Campus — San Pablo
Alabama
- Mobile Infirmary Medical Center — Mobile
Alaska
- Providence Cancer Center — Anchorage
Arkansas
- Highlands Oncology Group - Springdale — Bentonville
Colorado
- Poudre Valley Hospital — Fort Collins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2004-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086996
The ClinicalTrials.gov registry entry for NCT00086996 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 4 interventions — of which oxaliplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00086996 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Alabama, Alaska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00086996 about?
NCT00086996 is a clinical study titled "S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Oxaliplatin and fluorouracil may make tumor cells more sensitive to radi...
What is the current status of trial NCT00086996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2004-09. Estimated completion is 2011-08.
What conditions does trial NCT00086996 study?
This clinical trial studies the following conditions: Esophageal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00086996?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00086996?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00086996 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.